These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
351 related articles for article (PubMed ID: 30477736)
1. What is driving HTA decision-making? Evidence from cancer drug reimbursement decisions from 6 European countries. Maynou L; Cairns J Health Policy; 2019 Feb; 123(2):130-139. PubMed ID: 30477736 [TBL] [Abstract][Full Text] [Related]
2. Variation in Health Technology Assessment and Reimbursement Processes in Europe. Akehurst RL; Abadie E; Renaudin N; Sarkozy F Value Health; 2017 Jan; 20(1):67-76. PubMed ID: 28212972 [TBL] [Abstract][Full Text] [Related]
3. Health Technology Assessment (HTA) Case Studies: Factors Influencing Divergent HTA Reimbursement Recommendations in Australia, Canada, England, and Scotland. Allen N; Walker SR; Liberti L; Salek S Value Health; 2017 Mar; 20(3):320-328. PubMed ID: 28292476 [TBL] [Abstract][Full Text] [Related]
4. Disagreement on cancer drug decisions in Europe. Maynou L; Cairns J Int J Technol Assess Health Care; 2020 Jun; 36(3):232-238. PubMed ID: 32538341 [TBL] [Abstract][Full Text] [Related]
5. Determinants of Managed Entry Agreements in the context of Health Technology Assessment: a comparative analysis of oncology therapies in four countries. Efthymiadou O; Kanavos P Int J Technol Assess Health Care; 2021 Jan; 37():e31. PubMed ID: 33509311 [TBL] [Abstract][Full Text] [Related]
6. Why do health technology assessment coverage recommendations for the same drugs differ across settings? Applying a mixed methods framework to systematically compare orphan drug decisions in four European countries. Nicod E Eur J Health Econ; 2017 Jul; 18(6):715-730. PubMed ID: 27538758 [TBL] [Abstract][Full Text] [Related]
7. Associations between uncertainties identified by the European Medicines Agency and national decision making on reimbursement by HTA agencies. Bloem LT; Vreman RA; Peeters NWL; Hoekman J; van der Elst ME; Leufkens HGM; Klungel OH; Goettsch WG; Mantel-Teeuwisse AK Clin Transl Sci; 2021 Jul; 14(4):1566-1577. PubMed ID: 33786991 [TBL] [Abstract][Full Text] [Related]
8. The role of health technology assessment on pharmaceutical reimbursement in selected middle-income countries. Oortwijn W; Mathijssen J; Banta D Health Policy; 2010 May; 95(2-3):174-84. PubMed ID: 20074829 [TBL] [Abstract][Full Text] [Related]
9. Why do health technology assessment drug reimbursement recommendations differ between countries? A parallel convergent mixed methods study. Nicod E; Maynou L; Visintin E; Cairns J Health Econ Policy Law; 2020 Jul; 15(3):386-402. PubMed ID: 31488229 [TBL] [Abstract][Full Text] [Related]
10. Health technology assessment for cancer medicines across the G7 countries and Oceania: an international, cross-sectional study. Jenei K; Raymakers AJN; Bayle A; Berger-Thürmel K; Cherla A; Honda K; Jackson CCGA; Karikios D; Trapani D; Berry S; Gyawali B Lancet Oncol; 2023 Jun; 24(6):624-635. PubMed ID: 37269843 [TBL] [Abstract][Full Text] [Related]
11. Achieving equal and timely access to innovative anticancer drugs in the European Union (EU): summary of a multidisciplinary CECOG-driven roundtable discussion with a focus on Eastern and South-Eastern EU countries. Wilking N; Bucsics A; Kandolf Sekulovic L; Kobelt G; Laslop A; Makaroff L; Roediger A; Zielinski C ESMO Open; 2019; 4(6):e000550. PubMed ID: 31798977 [TBL] [Abstract][Full Text] [Related]
12. Reimbursement of biosimilars in Poland: is there a link to health technology assessment? Neumann D; Jabłecka A Expert Rev Pharmacoecon Outcomes Res; 2016 Dec; 16(6):781-792. PubMed ID: 26768654 [TBL] [Abstract][Full Text] [Related]
13. Impact of health technology assessment and managed entry schemes on reimbursement decisions of centrally authorised medicinal products in Belgium. Van Wilder P; Pirson M; Dupont A Eur J Clin Pharmacol; 2019 Jul; 75(7):895-900. PubMed ID: 30877328 [TBL] [Abstract][Full Text] [Related]
14. Comparing Use of Health Technology Assessment in Pharmaceutical Policy among Earlier and More Recent Adopters in the European Union. Beletsi A; Koutrafouri V; Karampli E; Pavi E Value Health Reg Issues; 2018 Sep; 16():81-91. PubMed ID: 30316029 [TBL] [Abstract][Full Text] [Related]
15. Trends and determinants in reimbursement decision-making in Poland in the years 2013-2015. Kawalec P; Malinowski KP; Trąbka W Expert Rev Pharmacoecon Outcomes Res; 2018 Apr; 18(2):197-205. PubMed ID: 28952400 [TBL] [Abstract][Full Text] [Related]
16. Health technology assessment and reimbursement policy for oncology orphan drugs in Central and Eastern Europe. Malinowski KP; Kawalec P; Trąbka W; Sowada C; Petrova G; Manova M; Savova A; Draganić P; Slabý J; Männik A; Márky K; Rugaja Z; Gulbinovic J; Tesar T; Paveliu MS Orphanet J Rare Dis; 2020 Oct; 15(1):277. PubMed ID: 33032634 [TBL] [Abstract][Full Text] [Related]
17. Dealing with Uncertainty and Accounting for Social Value Judgments in Assessments of Orphan Drugs: Evidence from Four European Countries. Nicod E; Berg Brigham K; Durand-Zaleski I; Kanavos P Value Health; 2017; 20(7):919-926. PubMed ID: 28712621 [TBL] [Abstract][Full Text] [Related]
18. The Development of the Romanian Scorecard HTA System. Radu CP; Chiriac ND; Pravat AM Value Health Reg Issues; 2016 Sep; 10():41-47. PubMed ID: 27881276 [TBL] [Abstract][Full Text] [Related]
19. A DECADE OF HEALTH TECHNOLOGY ASSESSMENT IN POLAND. Lipska I; McAuslane N; Leufkens H; Hövels A Int J Technol Assess Health Care; 2017 Jan; 33(3):350-357. PubMed ID: 28720170 [TBL] [Abstract][Full Text] [Related]
20. The correlation between HTA recommendations and reimbursement status of orphan drugs in Europe. Kawalec P; Sagan A; Pilc A Orphanet J Rare Dis; 2016 Sep; 11(1):122. PubMed ID: 27600717 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]